The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells
Open accessAbstract
Limited DNA end resection is the key to impaired homologous recombination in BRCA1-mutant cancer cells. Here, using a loss-of-function CRISPR screen, we identify DYNLL1 as an inhibitor of DNA end resection. The loss of DYNLL1 enables DNA end resection and restores homologous recombination in BRCA1-mutant cells, thereby inducing resistance to platinum drugs and inhibitors of poly(ADP-ribose) polymerase. Low BRCA1 expression correlates with increased chromosomal aberrations in primary ovarian carcinomas, and the junction sequences of somatic structural variants indicate diminished homologous recombination. Concurrent decreases in DYNLL1 expression in carcinomas with low BRCA1 expression reduced genomic alterations and increased homology at lesions. In cells, DYNLL1 limits nucleolytic degradation of DNA ends by associating with the DNA end-resection machinery (MRN complex, BLM helicase and DNA2 endonuclease). In vitro, DYNLL1 binds directly to MRE11 to limit its end-resection activity. Therefore, we infer that DYNLL1 is an important anti-resection factor that influences genomic stability and responses to DNA-damaging chemotherapy. DYNLL1 antagonizes end resection of DNA double-strand breaks, thereby inhibiting homologous repair, and the loss of DYNLL1 correlates with poor progression-free survival of patients with BRCA1-mutant ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citationOptimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637
Self-citationHigh‐resolution profiling of γH2AX around DNA double strand breaks in the mammalian genome
Iacovoni, J. S., Caron, P., Lassadi, I., Nicolas, E., Massip, L., Trouche, D., & Legube, G. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.38 · Cited by 515
Self-citation
Cited by
DNA double-strand break repair-pathway choice in somatic mammalian cells
Scully, R., Panday, A., Elango, R., & Willis, N. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0152-0 · Cited by 1,457
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00308-y · Cited by 972
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
PARP inhibitor resistance: the underlying mechanisms and clinical implications
Li, H., Liu, Z.-Y., Wu, N., Chen, Y.-C., Cheng, Q., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01227-0 · Cited by 539
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 505
Metadata
- Authors
- He, Y. J., Meghani, K., Caron, M.-C., Yang, C., Ronato, D. A., Bian, J., Sharma, A., Moore, J., Niraj, J., Detappe, A., Doench, J. G., Legube, G., Root, D. E., D’Andrea, A. D., Drané, P., De, S., Konstantinopoulos, P. A., Masson, J.-Y., & Chowdhury, D.
- Venue
- Nature
- Published
- 2018-10-31
- Volume
- 563
- Issue
- 7732
- Pages
- 522-526
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2899163437
- Cited by
- 219
- References
- 3
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells. https://app.cochat.ai/papers/10.1038/s41586-018-0670-5
- The paper
- He, Y. J., Meghani, K., Caron, M.-C., Yang, C., Ronato, D. A., Bian, J., Sharma, A., Moore, J., Niraj, J., Detappe, A., Doench, J. G., Legube, G., Root, D. E., D’Andrea, A. D., Drané, P., De, S., Konstantinopoulos, P. A., Masson, J.-Y., & Chowdhury, D. (2018). DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells. Nature. https://doi.org/10.1038/s41586-018-0670-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.